国际动态存档 （2015年8月3期）

• 8/19 FDA Grants Fast Track Designation to Cempra for Solithromycin in the Treatment of Community Acquired Bacterial Pneumonia 
• 8/19 Liraglutide Linked to Weight Loss Over 56 Weeks in T2DM
• 8/19 UPDATE 1-Amgen pays $71 mln to settle Enbrel, Aranesp marketing case
• 8/19 Boston firm’s diabetes treatment beats $6B Merck drug in head-to-head trial
• 8/19 FDA Approves Addyi (Flibanserin), 'A Milestone Moment' In Women's Health
• 8/19 AbbVie Requests Biosimilar Labeling Modification
• 8/18 FDA approves first treatment for sexual desire disorder
• 8/18 Big Pharma, rejoice: China aims to speed up approvals for new meds
• 8/18 Merck's Keytruda ready for quick FDA action on big melanoma expansion
• 8/18 ViewPoints: Roche eyes second-line NSCLC filing for atezolizumab, but is the prize still on the table?
• 8/18 Investigational IB1001 Effective for Breakthrough Bleeding in Patients With Haemophilia B: Presented at NHF 
• 8/18 FDA: Esperion Cholesterol Pill Will NOT Require Cardio Outcome Trials
• 8/18 Drinking coffee could prevent colon cancer's return: study
• 8/18 Insys Therapeutics' Dronabinol Oral Solution NDA Accepted for Filing by FDA 
• 8/18 Seattle Genetics Announces FDA Regular Approval of ADCETRIS® (Brentuximab Vedotin) for Classical Hodgkin Lymphoma Patients
• 8/18 Clinical trial using the body’s own immune cells to fight cancer leads to remission in most patientsE
• 8/18 Immunomedics Extends U.S. Patent Protection for Antibody-Drug Conjugate Program to 2033
• 8/17 Patient Death Does Not Augur Doom, But Kite Pharma Needs To Shut Its Big Mouth
• 8/17 You’re Better Than My Last Dance Partner But Still Not Perfect: Amgen Alleges that an Otherwise Complete Patent Dance Was Ruined by Pre-Approval Notice of Marketing
• 8/17 Will docs jump on new biosims? Survey shows they'll need some nudging
• 8/17 Novo Hypes Oral GLP1 Pill, Possible American Factory Plans
• 8/17 Endo Prevails: No Generic Opana ER Till 2023
• 8/17 The 5 Most Expensive Drugs in the World in 2015
• 8/17 European Commission Grants Marketing Authorisation for Unituxin™ (dinutuximab) for the Treatment of Paediatric High-Risk Neuroblastoma 
• 8/17 Kite Pharma Provides Update on KTE-C19 Clinical Trial
• 8/17 Roche's atezolizumab hits goals in PhII lung cancer trial 
• 8/17 FDA approves OxyContin for children 11 and older
• 8/14 Novo says new U.S. plant may be best bet to offset the FX bite
• 8/14 Merck tallies 36,000 job cuts in 5 years of restructuring
• 8/14 The top 5 vaccine makers by 2014 revenue
• 8/14 FDA approves OxyContin for children 11 and older 
• 8/14 GSK hopes big clinical trial can breath new life into lung drug
• 8/14 Compounded Drugs Blow $2 Billion Hole in Pentagon Budget 
• 8/14 Celldex and the limits of ‘overall survival benefit’ in cancer trials
• 8/14 New anti-cancer agent in sea sponges
• 8/14 Memory Problems Due to 'Cancer Brain' and Not 'Chemo Brain'?
• 8/14 This UNC researcher could change how cancer clinical trials measure side effects
• 8/13 The New England Journal Of Medicine Fact-Checks The Republican Debate
• 8/13 New Payment Models: It's Time to Move
• 8/13 Vitamin B3 pathway may lead to new obesity drugs